Bayer Aktiengesellschaft BAYRY
15.60 USD -0.06 (-0.38%)
As ofNov 16, 2026, 3:58 PM EST
15.59 Day range 15.80
7.65 52-week range 15.98
- YTD
- +44.18%
- 1 year
- +90.48%
News
zacks.com Bayer Wins FDA Approval for Sunharbo for Secondary Stroke Risk Reduction Bayer gains FDA approval for Sunharbo, the first Factor XIa inhibitor approved worldwide, opening new growth opportunities in stroke prevention.
businesswire.com Bayer's SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Bayer's SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With…
zacks.com 3 Large-Cap Stocks to Watch as Drug & Biotech Sector Rebounds in 2026 In the Large-Cap Pharmaceuticals industry, LLY, NVS and BAYRY are worth watching as the industry shows a strong recovery.
zacks.com BAYRY vs. JNJ: Which Stock Is the Better Value Option? Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Bayer Aktiengesellschaft (BAYRY) and Johnson & Johnson (JNJ). But which of these two stocks is…
zacks.com Are Medical Stocks Lagging Bayer (BAYRY) This Year? Here is how Bayer Aktiengesellschaft (BAYRY) and Encompass Health (EHC) have performed compared to their sector so far this year.
businesswire.com Bayer and America's Grow-a-Row Continue Partnership to Fight Food Insecurity PITTSTOWN, N.J.--(BUSINESS WIRE)-- #TeamBAYER--In 2026, Bayer and America's Grow-a-Row continued their longstanding partnership to combat food insecurity and expand access to fresh, nutritious…
reuters.com Bayer seeks bigger role in fast-growing Latin American biologicals market Bayer seeks bigger role in fast-growing Latin American biologicals market
zacks.com BAYRY Q3 Earnings and Revenues Miss Estimates, Pharma Performs Well Bayer's Q3 earnings and revenues miss estimates, but strong growth in Nubeqa and Kerendia boosts pharma performance and lifts 2026 EBITDA guidance.
businesswire.com Bayer to Present New Cardiovascular, Kidney and Stroke Data at the 2026 American Heart Association (AHA) Scientific Sessions WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that new data from its cardiovascular, kidney and stroke portfolios will be featured at the American Heart Association Scientific…
seekingalpha.com Bayer AG: Solid Q3 Earnings, But Still A 'Prove-It' Story Bayer A.G. maintains a 'Hold' rating after a robust Q3, with Pharma outperforming expectations and driving operating leverage. Q3 Pharma EBITDA before special items rose 23.6% to 1.292 billion euro,…
seekingalpha.com Bayer Aktiengesellschaft (BAYRY) Q3 2026 Earnings Call Transcript Bayer Aktiengesellschaft (BAYRY) Q3 2026 Earnings Call Transcript
marketbeat.com What Bayer Aktiengesellschaft (BAYN) Said on Its Q3 Earnings Call Bayer Aktiengesellschaft ETR: BAYN said it is on track to meet its 2026 commitments after reporting 3% organic sales growth and 7% adjusted EBITDA growth for the first nine months of the year,…
wsj.com Bayer Raises Earnings Outlook on Pharma Recovery The German group posted a recovery in its pharma arm after strong demand for key drugs allowed it to offset market pressures at its agricultural and consumer-health divisions.
reuters.com Bayer raises 2026 profit outlook Bayer raises 2026 profit outlook
wsj.com Bayer Gets in China Its First Global Approval for Stroke Prevention Drug The decision hands Bayer the first ever approval for a Factor XIa inhibitor, which aim to slow the activity of a protein that regulates how the body forms clots without increasing the risk of…
seekingalpha.com Bayer: Turnaround Is Gaining Momentum, But Debt Remains A Risk Bayer (OTCPK:BAYZF) remains a long-term Buy, with the stock still undervalued despite ongoing litigation and high debt levels. Litigation risks are easing, with a major Supreme Court win and a key…
businesswire.com Bayer to Present New Cardiac Amyloidosis and Heart Failure Data at the Heart Failure Society of America (HFSA) Annual Scientific Meeting WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that one late-breaking presentation along with five posters across its cardiovascular programs will be featured at the Heart…
zacks.com Bayer Seeks Kerendia Label Expansion in Non-Diabetic CKD BAYRY's Kerendia label expansion moves forward as FDA accepts an application for CKD patients without diabetes.
businesswire.com Actress and Menopause Advocate Melissa Joan Hart Partners with Bayer to Raise Awareness about Lynkuet® (elinzanetant), a Prescription Treatment for Moderate to Severe Hot Flashes due to Menopause WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced a partnership with actress and menopause advocate Melissa Joan Hart to increase awareness about Lynkuet® (elinzanetant) 60mg capsules, Bayer's…
businesswire.com U.S. FDA Accepts Bayer's Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer announced today that the U.S. Food and Drug Administration (FDA) accepted the company's supplemental New Drug Application (sNDA) for KERENDIA®…
